{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SOC+and+Active+Comparator",
    "query": {
      "intervention": "SOC and Active Comparator"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SOC+and+Active+Comparator&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T13:38:34.657Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04933799",
      "title": "IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Pneumonia"
      ],
      "interventions": [
        {
          "name": "PF-06650833",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Giovanni Franchin, M.D, Ph.D",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2021-01-06",
      "completion_date": "2022-05-06",
      "has_results": false,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04933799"
    },
    {
      "nct_id": "NCT03091439",
      "title": "Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteomyelitis"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2017-05-15",
      "completion_date": "2017-08-31",
      "has_results": true,
      "last_update_posted_date": "2018-09-26",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 1,
      "location_summary": "Ft. Pierce, Florida",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03091439"
    },
    {
      "nct_id": "NCT00488059",
      "title": "A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "enfuvirtide [Fuzeon]",
          "type": "DRUG"
        },
        {
          "name": "Optimized background ARV",
          "type": "DRUG"
        },
        {
          "name": "Integrase inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2007-06",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2011-07-22",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 41,
      "location_summary": "Hobson City, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Hobson City",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00488059"
    },
    {
      "nct_id": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML (Acute Myelogenous Leukemia)",
        "Acute Lymphoid Leukemia (ALL)",
        "Acute Leukemia (Category)",
        "MDS (Myelodysplastic Syndrome)",
        "CML (Chronic Myelogenous Leukemia)",
        "CLL (Chronic Lymphocytic Leukemia)",
        "Prolymphocyctic Leukemia",
        "Chronic Myelomonocytic Leukemia (CMML)",
        "Myeloproliferative Neoplasm (MPN)",
        "Lymphoma",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Conditioning Regimen A",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen B",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen C",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen D",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen E",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "PTCy (50 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "PTCy (25 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Growth Factors",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Blood Products",
          "type": "PROCEDURE"
        },
        {
          "name": "Supportive Care: Infection Prophylaxis",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Intravenous immune globulin (IVIG)",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Seizure prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Monitoring and management of CRS",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Lipid elevations",
          "type": "OTHER"
        },
        {
          "name": "Study treatment compliance",
          "type": "OTHER"
        },
        {
          "name": "Prohibited Concomitant Therapy",
          "type": "OTHER"
        },
        {
          "name": "Permitted Concomitant Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 358,
      "start_date": "2025-07-25",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06859424"
    },
    {
      "nct_id": "NCT04718389",
      "title": "A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "GSK3511294 (Depemokimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Benralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of care (SoC)",
          "type": "DRUG"
        },
        {
          "name": "Pre-filled Syringes (PFS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1717,
      "start_date": "2021-01-26",
      "completion_date": "2025-09-14",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 119,
      "location_summary": "Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04718389"
    },
    {
      "nct_id": "NCT06564844",
      "title": "A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Datopotamab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "UFT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-10-15",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 37,
      "location_summary": "Tucson, Arizona • Duarte, California • Glendale, California + 33 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06564844"
    },
    {
      "nct_id": "NCT06557122",
      "title": "Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcer"
      ],
      "interventions": [
        {
          "name": "SOC and Advanced Bioengineered Skin Substitute",
          "type": "DEVICE"
        },
        {
          "name": "SOC and Active Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Encoll Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2024-07-25",
      "completion_date": "2024-10-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • South Miami, Florida • Salem, Virginia",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Salem",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06557122"
    },
    {
      "nct_id": "NCT04869579",
      "title": "Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Selenium (as Selenious Acid)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "CHRISTUS Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-08-15",
      "completion_date": "2021-12-15",
      "has_results": false,
      "last_update_posted_date": "2021-08-03",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 1,
      "location_summary": "Longview, Texas",
      "locations": [
        {
          "city": "Longview",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04869579"
    },
    {
      "nct_id": "NCT05030012",
      "title": "Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infant, Premature",
        "Neonatal Respiratory Distress",
        "Oxygen Saturation",
        "Bronchopulmonary Dysplasia"
      ],
      "interventions": [
        {
          "name": "Automated Control",
          "type": "DEVICE"
        },
        {
          "name": "Manual Control",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Vapotherm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "2021-09-02",
      "completion_date": "2023-10-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Salt Lake City, Utah • Seattle, Washington",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05030012"
    },
    {
      "nct_id": "NCT07215273",
      "title": "Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Mould Infection"
      ],
      "interventions": [
        {
          "name": "EL219",
          "type": "DRUG"
        },
        {
          "name": "Active Comparator- IV Antifungal (LAmB or voriconazole)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-02-13",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-03T13:38:34.657Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07215273"
    }
  ]
}